Kurwanya Lymphoma hakoreshejwe uburyo bubiri bwo kuvura CAR-T

Umugore w'imyaka 61, wari waravuwe kenshi indwara ya diffuse large Lymphoma y'uturemangingo twa B, harimo imiti irindwi ya chimiotherapie, ubuvuzi bwa CAR-T, n'imiti myinshi ya PD-1 ivanze na chimiotherapie, byaje kumugora cyane. Nubwo yagerageje byinshi, ubuzima bwe ntibwari bwameze neza kugeza ubwo yageze muri BIOOCUS kugira ngo ahabwe ubuvuzi bwihariye.

Mu ntangiriro za 2021, ubwo lymphoma ye yagendaga yihuta cyane ikanatera ibisebe bikomeye ku ruhu no kubyimba, ubuzima bw'umurwayi bwasaga n'aho buteye ubwoba. Ayobowe n'itsinda ryihariye rya BIOOCUS, yatangiye urugendo rushya rwo kuvura. Nyuma yo kuvurwa bwa mbere, uburwayi bwe bwarahagaze, bituma akusanya no gukwirakwiza lymphocytes ze kugira ngo avurwe na CD19/CD22 CAR-T cell therapy.

Ku ya 19 Gashyantare 2021, yahawe selile ebyiri za CAR-T. Nubwo yagize ingaruka mbi zishobora gukemuka, isuzuma rya PET-CT ryakurikiyeho ryagaragaje iterambere rikomeye. Muri Werurwe, yageze ku rwego rwo kugabanya burundu uburwayi bwe, biba ihinduka rikomeye mu rugamba rwe rwo kurwanya kanseri.

Ubu, amaze imyaka itatu avurwa na CAR-T, asangiza inkuru ye yo gukira mu ishami rya kane. Lymphoma yo mu Bushinwa Inama y'Abarwayi, itera inkunga abandi bahura n'ibibazo nk'ibyo. Urugendo rwe rugaragaza iterambere mu buvuzi bwa CAR-T n'uruhare rw'ingenzi rw'ubuvuzi bwihariye mu kuvura kanseri y'urukozasoni.

Kubera ubuvuzi bwuzuye muri BIOOCUS, akomeje gutera imbere, ashimangira akamaro ko kuvurwa mu buryo bushya no gushyigikira abaganga b’inzobere mu by’ubuzima mu kurwanya kanseri.